Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.

Fecha de publicación: Fecha Ahead of Print:

Autores de INCLIVA

Participantes ajenos a INCLIVA

  • Lombardi, Pasquale

Grupos y Plataformas de I+D+i

Abstract

INTRODUCTION: Molecular-matched therapies have revolutionized cancer treatment. We evaluated the improvement in clinical outcomes of applying an in-house customized Next Generation Sequencing panel in a single institution. METHODS: Patients with advanced solid tumors were molecularly selected to receive a molecular-matched treatment into early phase clinical trials versus best investigators choice, according to the evaluation of a multidisciplinary molecular tumor board. The primary endpoint was progression-free survival (PFS) assessed by the ratio of patients presenting 1.3-fold longer PFS on matched therapy (PFS2) than with prior therapy (PFS1). RESULTS: Of a total of 231 molecularly screened patients, 87 were eligible for analysis. Patients who received matched therapy had a higher median PFS2 (6.47 months; 95% CI, 2.24-14.43) compared to those who received standard therapy (2.76 months; 95% CI, 2.14-3.91, Log-rank p = 0.022). The proportion of patients with a PFS2/PFS1 ratio over 1.3 was significantly higher in the experimental arm (0.33 vs 0.08; p = 0.008). DISCUSSION: We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of a customized NGS panel. This process optimizes the selection of available therapies, improving disease control. Prospective randomized trials are needed to confirm this approach and open the door to expanded drug access.

© 2021. The Author(s).

Datos de la publicación

ISSN/ISSNe:
0007-0920, 1532-1827

BRITISH JOURNAL OF CANCER  NATURE PUBLISHING GROUP

Tipo:
Article
Páginas:
1261-1269
PubMed:
34493820

Citas Recibidas en Web of Science: 27

Documentos

Métricas

Filiaciones mostrar / ocultar

Financiación

Proyectos y Estudios Clínicos

CONTRATOS JUAN RODES

Investigador Principal: DESAMPARADOS RODA PEREZ

2016/197 . INSTITUTO SALUD CARLOS III . 2017

Plataformas biobancos PT17/0015/0049

Investigador Principal: ANTONIO FERRANDEZ IZQUIERDO

PT17/0015/0049 . INSTITUTO SALUD CARLOS III . 2018

Macrófagos asociados al tumor, angiogénesis tumoral y resistencia a las terapias en Cáncer Gástrico Difuso fenotipo Mesenquimal.

Investigador Principal: TANIA CAROLINA FLEITAS KANONNIKOFF

PI18/01508 . INSTITUTO SALUD CARLOS III . 2019

Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides

Investigador Principal: ANDRÉS CERVANTES RUIPEREZ

PI18/01909 . INSTITUTO SALUD CARLOS III . 2019

Cita

Compartir